Selection of recent projects:
Client: NUMARES, Regensburg, Germany
Lipopredict - Prognostic value of NMR lipid subfractions on cardiovascular risk
in the LURIC study
The aim of the project is to develop a novel lipid risk score including lipid subfractions measured by NMR technology in different risk settings and different patient subpopulations of the LURIC study. Renopredict - A novel biomarker score for prediction of cardiovascular risk and mortality in diabetes patients on hemodialysis.
Renopredict - A novel biomarker score for prediction of cardiovascular risk
Client: Department of Nephrology, University of Würzburg, Germany
and mortality in diabetes patients on hemodialysis
The aim of the project is to derive a scoring system for prediction of cardiovascular risk and mortality in diabetes patients on hemodialysis. Prognostic models are derived from follow-up data of the Deutsche Diabetes Dialyse Study (4D study).
Plant sterols and cardiovascular risk. A meta-analysis of epidemiological studiesClient: Danone Research, Palaiseau, France
The impact of increased serum concentrations of plant sterols on cardiovascular risk is unclear. BGStats was contraczed to conduct a systematic review and meta-analysis aimed to investigate whether there is an association between serum concentrations of two common plant sterols (sitosterol, campesterol) and cardiovascular disease (CVD).
Quantification of HDL proteins, cardiac events and mortality in type 2 diabetes patients on hemodialysis - A Post-Hoc Analysis from the 4D Study
Client: Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria
There is a need for novel biomarkers related to high density lipoprotein (HDL) cholesterol HDL that better quantify the prognostic effect than the total serum concentration. We evaluated the prognostic effect of serum amyloid A (SAA) and surfactant-protein B (HDL) in patients with type 2 diabetes on hemodialysis participating in the German Diabetes and Dialysis Study (4D Study).
Effect of high-flux dialysis on circulating FGF-23 concentrations in ESRD patients: results from a randomised trialClient: Department of Nephrology, University of Würzburg, Germany
In patients undergoing hemodialysis increased concentrations of circulating fibroblast growth factor-23 (FGF-23) are independently associated with cardiovascular events and mortality. We conducted a post-hoc analysis of a randomized trial (the MINOXIS study) aimed to compare the impact of high-flux versus low-flux hemodialysis on circulating FGF-23 concentrations.